Abstract: Objective To study the clinical efficacy and economic effectiveness of biochemotherapy in the treatment of aging advanced non-small-cell lung cancer.Methods A total of 56 advanced non small cell lung carcinoma patients were random divided into two groups according to the different chemotherapy regimens applied by using cost-effectiveness analysis in pharmacoeconomics.Treatment group:Twenty-eight cases with non small cell lung carcinoma were enrolled and underwent chemotherapy with pemetrexed disodium,two cycle therapy followed by transfusion of CIK treatment,one cycle therapy.Control group:Twenty-eight cases with non small cell lung cancer were enrolled and only underwent chemotherapy,two cycle therapy.Results In treatment group,of the 28 cases,2 were CR,18 were PR,effective power is 67.9%;In control group,of the 28 cases,0 were CR,9 were PR,effective power is 32.1%.two groups contrast is obviously significant.Average cost is 37800 yuan in treatment group and 21038 yuan in control group,but cost-effectiveness in treastment group is lower than that in control group,two group contrast is obviously significant.Conclusions Patients with biochemotherapy can benefit from the combination of chemotherapy and autologous CIK transfusion.The treatment can enhance the efficacy of aging advanced non-small-cell lung cancer,and is a acceptable treatment modality in economic effectiveness.